Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial

Autor: Renato D. Lopes, Celestia S. Higano, Susan F. Slovin, Adam J. Nelson, Robert Bigelow, Per S. Sørensen, Chiara Melloni, Shaun G. Goodman, Christopher P. Evans, Jan Nilsson, Deepak L. Bhatt, Noel W. Clarke, Tine K. Olesen, Belinda T. Doyle-Olsen, Henriette Kristensen, Lauren Arney, Matthew T. Roe, John H. Alexander, Mirjam Mol-Arts, Samreen Mansor-Lefebvre, Konstantin Zubovskiy, Allan Blemings, Klaus Dugi, Gerald Bloomfield, Chris Kontos, Adam DeVore, Dedrick Jordan, Bradley Kolls, Robin Matthews, Rajendra Mehta, Thomas J. Povsic, Michael Morse, Kenneth W. Mahaffey, Susan Halabi, Darryl Leong, Laurence Klotz, Neil Fleshner, Godfrey Jansz, Jonathan Giddens, Russell Egerdie, Joseph Chin, Joseph Zadra, Richard Casey, Jean Simard, Tamim Niazi, André-Guy Martin, Marek Babjuk, Jaroslav Hajek, Jiri Klecka, Jiri Kubes, Jan Schraml, Jitka Jakesova, Jaroslav Vanasek, Bohuslav Melichar, Heikki Seikkula, Manouar Samir Abdiche, Marc Colombel, Philippe Debourdeau, Gregoire Robert, Arnauld Villers, Guillaume Ploussard, Benjamin Pradere, Franck Bruyere, Jean-Luc Descotes, Idir Ouzaid, Alexander Winter, Herbert Hanitzsch, Herbert Sperling, Ralf Eckert, Peter Hammerer, Elke Stagge, Florian Seseke, Silvio Szymula, Aristotelis Bamias, Anastasios Thanos, Konstantinos Hatzimouratidis, Charalambos Mamoulakis, Haralabos Kalofonos, Elzbieta Oszukowska, Katarzyna Madziarska, Jacek Fijuth, Mateusz Obarzanowski, Boris Alekseev, Vagif Atduev, Dmitri Pushkar, Evgeniy Veliev, Alexander Zyryanov, Sergey Petrov, Evgeny Kopyltsov, Vadim Kozlov, Ladislav Macko, Jozef Dubravicky, Richard Polak, Obaidullah Mir, Marek Vargovcak, Ivan Mincik, Jan Kliment, Frederico Goncalves, Juraj Mikulas, Roman Sokol, Michal Korcek, Jozef Marko, Viktor Kovacik, Igor Milichovsky, Pavol Dubinsky, John Lazarus, Sanjay Dixit, Euan Green, Rajaguru Srinivasan, Danish Mazhar, Yeung Ng, Naveed Sarwar, Craig Herman, Frederick Snoy, Robert Given, Ronald Suh, David Lipsitz, James Bailen, Lawrence Gervasi, Idalia Acosta, Laurence Belkoff, Ning Wu, Jeffrey Frankel, Lawrence Karsh, Bryant Poole, David Lieber, Jason Engel, Mohamed Bidair, Steven Rosenberg, Paul Sieber, Adam Perzin, Susan Kalota, Amar Singh, Ralph Henderson, Jeffrey Wayne, Moben Mirza, Richard D’Anna, Fredrick Wolk, Osvaldo Padron, Kathryn Bylow, Jonathan Rubenstein, Benjamin Gartrell, Michael Schwartz, Kalpesh Patel, Ajit Maniam, Thomas Keane, Michael Goodman, Charles Bane, Michael Chung, Stephen Savage, Edward Uchio, Son Nguyen, William Aronson, Rakesh Khanna, Carlton Barnswell

Publikováno v: Circulation. 144(16)

Background: The relative cardiovascular safety of gonadotropin-releasing hormone (GnRH) antagonists compared with GnRH agonists in men with prostate cancer and known atherosclerotic cardiovascular disease remains controversial. Methods: In this inter

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd9271ccb4eb75e7486635b0056df019
https://pubmed.ncbi.nlm.nih.gov/35312383

Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial

Autor: Isabelle, Monnet, Alain, Vergnenègre, Gilles, Robinet, Henri, Berard, Regine, Lamy, Lionel, Falchero, Sabine, Vieillot, Roland, Schott, Charles, Ricordel, Stephane, Chouabe, Pascal, Thomas, Radj, Gervais, Anne, Madroszyk, Samir, Abdiche, Anne Marie, Chiappa, Laurent, Greillier, Chantal, Decroisette, Jean Bernard, Auliac, Christos, Chouaïd

Publikováno v: Therapeutic Advances in Medical Oncology

Background: The role and timing of whole or stereotaxic brain radiotherapy (BR) in patients with advanced non-small cell lung cancer (aNSCLC) and asymptomatic brain metastases (aBMs) are not well established. This study investigates whether deferring

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::4cbebf335ad2f21d736f4dd36a0830cb
https://pubmed.ncbi.nlm.nih.gov/33948123

Chemoradiotherapy with FOLFOX plus cetuximab in locally advanced oesophageal cancer: The GERCOR phase II trial ERaFOX

Autor: Benoist Chibaudel, Frédéric Di Fiore, Gérard Lledo, Astrid Pozet, Pascal Artru, Nicolas Jovenin, Olivier Dupuis, Valérie Blondin, Mohamed Attia, Laurent Mineur, Aimery de Gramont, Laetitia Dahan, Menouar Samir Abdiche, Franck Bonnetain, Florence Huguet, Marie-Pierre Galais

Publikováno v: European Journal of Cancer. 56:115-121

Background To determine efficacy and toxicity of radiation therapy combined with oxaliplatin, 5-fluorouracil, and folinic acid (FOLFOX) and cetuximab in patients with locally advanced oesophageal cancer. Patients and methods Patients with stage III o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2254bd092d5e6aeee5a101aba2aec2d4
https://doi.org/10.1016/j.ejca.2015.12.020